Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 21 (32), 9577-87

Reduction in Duodenal Endocrine Cells in Irritable Bowel Syndrome Is Associated With Stem Cell Abnormalities

Affiliations

Reduction in Duodenal Endocrine Cells in Irritable Bowel Syndrome Is Associated With Stem Cell Abnormalities

Magdy El-Salhy et al. World J Gastroenterol.

Abstract

Aim: To determine whether the decreased density of duodenal endocrine cells in irritable bowel syndrome (IBS) is associated with abnormalities in stem cell differentiation.

Methods: The study sample comprised 203 patients with IBS (180 females and 23 males with a mean age of 36 years) and a control group of 86 healthy subjects without gastrointestinal complaints (77 females and 9 males with a mean age of 38 years). The patients included 80 with mostly diarrhoea (IBS-D), 47 with both diarrhoea and constipation (IBS-M), and 76 with mostly constipation (IBS-C). Both the patients and controls underwent gastroscopy and four biopsy samples were taken from the descending part of the duodenum, proximal to the papilla of Vater. The biopsy samples were sectioned and immunostained for Musashi 1 (Msi-1), neurogenin 3 (NEUROG3), secretin, cholecystokinin (CCK), gastric inhibitory peptide (GIP), somatostatin and serotonin. Immunostaining was performed with an ultraView Universal DAB Detection Kit (v1.02.0018, Venata Medical Systems, Basal, Switzerland) using the BenchMark Ultra immunohistochemistry/in situ hybridization staining module (Venata Medical Systems). Endocrine cell densities were quantified by computerized image analysis using the Olympus cellSens imaging program.

Results: The densities of Msi-1 and NEUROG3 cells were significantly lower in IBS patients, regardless of the subtype, than in the controls (77 ± 17 vs 8 ± 2; P = 0.0001, and 351 ± 33 vs 103 ± 22; P = 0.00002, respectively). Furthermore, the densities of secretin, and CCK cells were significantly lower in patients with diarrhoea as the predominant IBS symptom (IBS-D) than in the controls (161 ± 11 vs 88 ± 8; P = 0.00007, and 325 ± 41 vs 118 ± 10; P = 0.00006, respectively), but not in patients with constipation as the predominant IBS symptom (IBS-C) or those with both diarrhoea and constipation (IBS-M). The GIP cell density was significantly reduced in both IBS-D (152 ± 12 vs 82 ± 7; P = 0.00003), and IBS-C (152 ± 12 vs 107 ± 8; P = 0.01), but not in IBS-M. The densities of somatostatin cells in the controls and the IBS-total, IBS-D, IBS-M and IBS-C patients were 81 ± 8, 28 ± 3, 20 ± 4, 37 ± 5 and 28 ± 4 cells/mm(2) epithelium, respectively. The density of somatostatin cells was lower in IBS-total, IBS-D, IBS-M and IBS-C patients than in the controls (P = 0.00009, 0.00006, 0.009 and 0.00008, respectively). The density of serotonin cells did not differ between IBS patients and controls.

Conclusion: The reduction in duodenal endocrine cells in IBS patients found in this study is probably attributable to the reduction in cells expressing Msi-1 and NEUROG3.

Keywords: Cholecystokinin; Irritable bowel syndrome; Musashi-1; Neurogenin 3; Secretin; Somatostatin.

Figures

Figure 1
Figure 1
Densities of musashi 1 and neurogenin 3 cells in controls and irritable bowel syndrome-total, irritable bowel syndrome-C, irritable bowel syndrome-D and irritable bowel syndrome-M patients. aP < 0.05, bP < 0.001 vs the control group.
Figure 2
Figure 2
Musashi-1-immunoreactive cells (arrows) in representative subjects from the (A) control, (B) irritable bowel syndrome-D, (C) irritable bowel syndrome-M and (D) irritable bowel syndrome-C patients.
Figure 4
Figure 4
Densities of secretin, cholecystokinin, gastric inhibitory peptide, somatostatin and serotonin cells in controls and irritable bowel syndrome-total, irritable bowel syndrome-D, irritable bowel syndrome-M and irritable bowel syndrome-C patients. aP < 0.05, bP < 0.001 vs the control group.
Figure 5
Figure 5
Secretin cells (arrows) in (A) a control subject (B) irritable bowel syndrome-D, (C) irritable bowel syndrome-M and (D) irritable bowel syndrome-C patients.
Figure 6
Figure 6
Cholecystokinin-immunoreactive cells (arrows) in (A) a control subject (B) irritable bowel syndrome-D, (C) irritable bowel syndrome-M and (D) irritable bowel syndrome-C patients.
Figure 7
Figure 7
Gastric inhibitory peptide cells (arrows) in (A) a control subject (B) irritable bowel syndrome-D, (C) irritable bowel syndrome-M and (D) irritable bowel syndrome-C patients.

Similar articles

See all similar articles

Cited by 11 articles

See all "Cited by" articles

MeSH terms

Feedback